Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Journal: Nature communications
Published: December 03, 2022
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Journal: Clinical hematology international
Published: August 25, 2022
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
Journal: Journal of clinical pharmacology
Published: May 18, 2021
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects.
Journal: The Journal of pharmacology and experimental therapeutics
Published: March 19, 2021
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Journal: Prostate cancer and prostatic diseases
Published: November 28, 2018
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 09, 2018
Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data.
Journal: Journal of the National Cancer Institute
Published: May 11, 2018
Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.
Journal: The breast journal
Published: February 08, 2017
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 09, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.
Journal: Leukemia research
Published: May 25, 2016
A (heat) shocking development: FBXW7 loss unleashes HSF1 to drive melanoma invasion and metastasis.
Journal: Pigment cell & melanoma research
Published: July 17, 2015
In Reply to Bhattacharyya et al.
Journal: International journal of radiation oncology, biology, physics
Published: June 10, 2015
Last Updated: 09/26/2026